In the claims:

Please amend the claims as follows:

Claims 1-8. **(Canceled)**

1 9. **(Previously presented)** An isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a K_d of 1×10^{-10} M or less and a k_{off} rate constant of 1×10^{-3} s^{-1} or less, as determined by surface plasmon resonance.

2 10. **(Previously presented)** The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of 1×10^{-4} s^{-1} or less.

3 11. **(Previously presented)** The isolated human antibody of claim 9, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of 1×10^{-5} s^{-1} or less.

8 12. **(Previously presented)** The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-9} M or less.

9 13. **(Previously presented)** The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-10} M or less.

10 14. **(Previously presented)** The neutralizing antibody of claim 143, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-11} M or less.

Claims 15-40. **(Canceled)**

16 ~~41.~~ **(Original)** An isolated human antibody, or an antigen-binding portion thereof, which

a) inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-9}M or less;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26.

17 ~~42.~~ **(Original)** 16 The isolated human antibody, or an antigen-binding portion thereof, of claim ~~41~~ which further has a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27; and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28.

18 ~~43.~~ **(Original)** 16 The isolated human antibody, or an antigen-binding portion thereof, of claim ~~41~~ which further has a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29; and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.

21 ~~44.~~ **(Original)** An isolated human antibody, or an antigen-binding portion thereof, having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32.

22 ~~45.~~ **(Original)** The isolated human antibody of claim ~~44~~ 21, comprising a heavy chain constant region selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions.

23 ~~46.~~ **(Original)** The isolated human antibody of claim ~~45~~ 22, wherein the antibody heavy chain constant region is IgG1.

24 ~~47.~~ **(Original)** The isolated human antibody of claim ~~44~~ 21, which is a Fab fragment.

25 ~~48~~ **(Original)** The isolated human antibody of claim ~~44~~ 21, which is a $F(ab')_2$ fragment.

~~49.~~ **(Original)** The isolated human antibody of claim ~~44~~, which is a single chain Fv fragment.

Claims 50-87. **(Canceled)**

~~88.~~ **(Previously presented)** A pharmaceutical composition comprising the antibody or an antigen binding portion thereof, of claim ~~9~~, ~~41~~, ~~44~~, ~~151~~, ~~153~~, ~~164~~, ~~167~~, ~~168~~, ~~172~~, ~~183~~, or ~~184~~, and a pharmaceutically acceptable carrier.

Claims 89-90 **(Canceled)**

~~91.~~ **(Previously presented)** The pharmaceutical composition of claim ~~88~~, further comprising an additional therapeutic agent selected from the group consisting of budenoside, corticosteroids, cyclosporin, sulfasalazine, aminosalicylates, 6-mercaptopurine, azathioprine, metronidazole, mesalamine, olsalazine, balsalazide, antioxidants, antibodies to IL-1 receptor, anti-IL-1β monoclonal antibodies, anti-IL-6 monoclonal antibodies, pyridinyl-imidazole compounds, anti-TNF antibodies, or fragments thereof, and anti-LT antibodies.

Claims 92-141. **(Canceled)**

~~142.~~ **(Previously presented)** The isolated human antibody, or antigen-binding portion thereof, of claim 9, which is a recombinant antibody, or antigen-binding portion thereof.

~~143.~~ **(Previously presented)** The isolated human antibody of any one of claims ~~9~~ to ~~11~~, wherein the antibody is a neutralizing antibody.

~~144.~~ **(Previously presented)** The neutralizing antibody of claim ~~143~~, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* phytohemagglutinin blast proliferation assay (PHA assay) with an IC_{50} of 1 x 10^{-7} M or less.

12 ~~145.~~ **(Previously presented)** The neutralizing antibody of claim ~~143~~ 7, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-8} M or less

13 ~~146.~~ **(Previously presented)** The neutralizing antibody of claim ~~143~~ 7, or an antigen-binding portion thereof, which inhibits human IFNγ production with an IC_{50} of 1×10^{-10} M or less.

14 ~~147.~~ **(Previously presented)** The neutralizing antibody of claim ~~143~~ 7, or an antigen-binding portion thereof, which inhibits human IFNγ production with an IC_{50} of 1×10^{-11} M or less.

15 ~~148.~~ **(Previously presented)** The neutralizing antibody of claim ~~143~~ 7, or an antigen-binding portion thereof, which inhibits human IFNγ production with an IC_{50} of 5×10^{-12} M or less.

19 ~~149.~~ **(Previously presented)** 16 The isolated human antibody, or antigen-binding portion thereof, of claim ~~41~~, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-10} M or less.

20 ~~150.~~ **(Previously presented)** 16 The isolated human antibody, or antigen-binding portion thereof, of claim ~~41~~, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-11} M or less.

27 ~~151.~~ **(Previously presented)** An isolated human antibody, or an antigen-binding portion thereof, which dissociates from human IL-12 with a K_d of 1×10^{-10} M or less and binds to an epitope on the p40 subunit of human IL-12.

28 ~~152.~~ **(Previously presented)** The isolated human antibody of claim ~~151~~ 27, which neutralizes the activity of human IL-12.

29 ~~153.~~ **(Currently amended)** A neutralizing isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a k_{off} rate constant of $1 \times 10^{-2}\ s^{-1}$ ~~$1 \times 10^{-3}\ s^{-1}$~~ or less, as determined by surface plasmon resonance.

30 154. **(Currently amended)** The neutralizing isolated human antibody of claim ~~153,~~ or an antigen-binding portion thereof, which dissociates from human IL-12 with a 29 k_{off} rate constant of 1×10^{-4} s^{-1} or less.

31 ~~155.~~ **(Previously presented)** The neutralizing isolated human antibody of claim ~~153,~~ 29 or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of 1×10^{-5} s^{-1} or less.

33 ~~156.~~ **(Currently amended)** The neutralizing isolated human antibody of any one of claims ~~153~~ 29 to ~~155~~ 31 and 207, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-7} M or less 32

34 ~~157.~~ **(Currently amended)** The neutralizing isolated human antibody of any one of claims ~~153~~ 29 to ~~155~~ 31 and 207, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation 32 in an *in vitro* PHA assay with an IC_{50} of 1×10^{-8} M or less.

35 ~~158.~~ **(Currently amended)** 32 The neutralizing isolated human antibody of any one of claims ~~153~~ 29 to ~~155~~ 31 and 207, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-9} M or less.

36 ~~159.~~ **(Currently amended)** 32 The neutralizing isolated human antibody of any one of claims ~~153~~ 29 to ~~155~~ 31 and 207, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-10} M or less.

37 ~~160.~~ **(Currently amended)** 32 The neutralizing isolated human antibody of any one of claims ~~153~~ 29 to ~~155~~ 31 and 207, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-11} M or less.

38 ~~161.~~ **(Currently amended)** 32 The neutralizing isolated human antibody of any one of claims ~~153~~ 26 to ~~155~~ 31 and ~~207~~, or an antigen-binding portion thereof, which inhibits human IFNγ production with an IC_{50} of 1×10^{-10} M or less.

39 ~~162.~~ **(Currently amended)** 32 The neutralizing isolated human antibody of any one of claims ~~153~~ 26 to ~~155~~ 31 and ~~207~~, or an antigen-binding portion thereof, which inhibits human IFNγ production with an IC_{50} of 1×10^{-11} M or less.

40 ~~163.~~ **(Currently amended)** 32 The neutralizing isolated human antibody of any one of claims ~~153~~ 26 to ~~155~~ 31 and ~~207~~, or an antigen-binding portion thereof, which inhibits human IFNγ production with an IC_{50} of 5×10^{-12} M or less.

41 ~~164.~~ **(Previously presented)** An isolated human antibody, or an antigen-binding portion thereof, which

a) dissociates from human IL-12 with a k_{off} rate constant of 1×10^{-3} s^{-1} or less, as determined by surface plasmon resonance;

b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25; and

c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26.

42 ~~165.~~ **(Previously presented)** The isolated human antibody of claim 41 ~~164~~, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of 1×10^{-4} s^{-1} or less.

43 ~~166.~~ **(Previously presented)** The isolated human antibody of claim 41 ~~164~~, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of 1×10^{-5} s^{-1} or less.

44 ~~167.~~ **(Previously presented)** An isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and comprises:

a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 26; and

a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 25.

45 45

~~168.~~ **(Previously presented)** An isolated human antibody, or an antigen-binding portion thereof, with a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 26, and with a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 25.

46 ~~169.~~ **(Previously presented)** 45 The isolated human antibody, or an antigen-binding portion thereof, of claim ~~168,~~ wherein the LCVR further has a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 28 and the HCVR further has a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 27.

47 ~~170.~~ **(Previously presented)** 46 The isolated human antibody, or an antigen-binding portion thereof, of claim ~~169,~~ wherein the LCVR further has CDR1 domain comprising the amino acid sequence of SEQ ID NO: 30 and the HCVR has a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 29.

69 ~~171.~~ **(Previously presented)** A pharmaceutical composition comprising an antibody or an antigen binding portion thereof, and a pharmaceutically acceptable carrier, wherein the antibody comprises:

a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 26; and

a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 25.

48 ~~172.~~ **(Previously presented)** An isolated human antibody that binds human IL-12 and is the antibody J695, or an antigen binding portion thereof.

49 ~~173.~~ **(Previously presented)** 48 A pharmaceutical composition comprising the isolated human antibody of claim ~~172~~ and a pharmaceutically acceptable carrier.

Claims 174-182. **(Canceled)**

50

~~183.~~ **(Previously presented)** An isolated human antibody, or antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a K_d of 1.34×10^{-10} M or less, and neutralizes human IL-12.

50 51

~~184.~~ **(Previously presented)** The isolated human antibody of claim ~~183~~, or an antigen-binding portion thereof, which dissociates from human IL-12 with a K_d of 9.74×10^{-11} M or less.

52

~~185.~~ **(Previously presented)** The isolated human antibody, or antigen-binding portion thereof, of claims ~~183~~ or ~~184~~, which is a recombinant antibody, or antigen-binding portion thereof.

52

53 ~~186.~~ **(Previously presented)** The isolated human antibody of claim ~~185~~, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-7} M or less.

52

54 ~~187.~~ **(Previously presented)** The isolated human antibody of claim ~~185~~, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-8} M or less

52

55 ~~188.~~ **(Previously presented)** The isolated human antibody of claim ~~185~~, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-9} M or less.

52

56 ~~189.~~ **(Previously presented)** The isolated human antibody of claim ~~185~~, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-10} M or less.

52

57 ~~190.~~ **(Previously presented)** The isolated human antibody of claim ~~185~~, or an antigen-binding portion thereof, which inhibits phytohemagglutinin blast proliferation in an *in vitro* PHA assay with an IC_{50} of 1×10^{-11} M or less.

58 52

~~191.~~ **(Previously presented)** The isolated human antibody of claim ~~185,~~ or an antigen-binding portion thereof, which inhibits human IFNγ production with an IC_{50} of 1 x 10^{-10} M or less.

59 52

~~192.~~ **(Previously presented)** The isolated human antibody of claim ~~185,~~ or an antigen-binding portion thereof, which inhibits human IFNγ production with an IC_{50} of 1 x 10^{-11} M or less.

60 52

~~193.~~ **(Previously presented)** The isolated human antibody of claim ~~185,~~ or an antigen-binding portion thereof, which inhibits human IFNγ production with an IC_{50} of 5 x 10^{-12} M or less.

61 52

~~194.~~ **(Previously presented)** The isolated human antibody of claim ~~185,~~ or an antigen-binding portion thereof, which inhibits IL-12 binding to its receptor in an IL-12 receptor binding assay (RBA) with an IC_{50} of 1 x 10^{-9} M or less.

62 52

~~195.~~ **(Previously presented)** The isolated human antibody of claim ~~185,~~ or an antigen-binding portion thereof, which inhibits IL-12 binding to its receptor in an IL-12 receptor binding assay (RBA) with an IC_{50} of 1 x 10^{-10} M or less.

63 52

~~196.~~ **(Previously presented)** The isolated human antibody of claim ~~185,~~ or an antigen-binding portion thereof, which inhibits IL-12 binding to its receptor in an IL-12 receptor binding assay (RBA) with an IC_{50} of 1 x 10^{-11} M or less.

64 64

~~197.~~ **(Previously presented)** The pharmaceutical composition of claim ~~86,~~ further comprising an additional therapeutic agent selected from the group consisting of anti- IL-1 antibodies, anti-IL-2 antibodies, anti- IL-6 antibodies, anti-IL-7 antibodies, anti-IL-8 antibodies, anti- IL-15 antibodies, anti- IL-16 antibodies, anti-IL-18 antibodies, anti- EMAP-II antibodies, anti-GM-CSF antibodies, anti-FGF antibodies, anti- PDGF antibodies, anti-CD2 antibodies, anti-CD3 antibodies, anti-CD4 antibodies, anti-CD8 antibodies, anti-CD25 antibodies, anti-CD28 antibodies, anti-CD30 antibodies, anti-CD40 antibodies, anti-CD45 antibodies, anti-CD69 antibodies, anti-CD80 (B7.1) antibodies, anti-CD86 (B7.2) antibodies, and anti-CD90 antibodies.

67 64

198. **(Previously presented)** The pharmaceutical composition of claim 88, further comprising an additional therapeutic agent selected from the group consisting of methotrexate, FK506, rapamycin, mycophenolate mofetil, leflunomide, non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen, prednisolone, 6-mercaptopurines, soluble p55 TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R, sIL-13, antiinflammatory cytokines, IL-4, IL-10, IL-11, IL-13, TGFβ, Vx740, anti-P7s, p-selectin glycoprotein ligand (PSGL), p75TNFRIgG (Enbrel™), p55TNFRIgG (Lenercept™), pyridinyl-imidazole compounds, anti-gp39 antibodies, anti-CD40L antibodies, methotrexate, cytokine suppressive anti-inflammatory drugs (CSAIDs), leflunomide, MP, mesalazine, chloroquinine/hydroxychloroquine, pencillamine, aurothiomalate, cochicine, salbutamol, terbutaline, salmeteral, theophylline, aminophylline, cromoglycate, nedocromil, ketotifen, ipratropium, and oxitropium.

68 64

199. **(Previously presented)** The pharmaceutical composition of claim 88, further comprising an additional therapeutic agent selected from the group consisting of anti-IRAK antibodies, anti-NIK antibodies, anti-IKK antibodies, anti-p38 antibodies, D2E7, cA2 (Remicade™), CDP 571, 5-aminosalicylic acid, TNFR-Ig constructs, dexamethasone, aminosalicylic acid, IL-1ra, methylprednisolone, cyclophosphamide, methotrexate, 4-aminopyridine, tizanidine, interferon-β1a (Avonex™), interferon-β1b (Betaseron™), Copolymer 1 (Cop-1; Copaxone™), hyperbaric oxygen, clabribine, anti-EMAP-II antibodies, IFNβ1a, IFNβ1b, and IL-1.

70

200. **((Previously presented)** A pharmaceutical composition comprising the antibody or an antigen binding portion thereof of claim 143, and a pharmaceutically acceptable carrier.

7 70

71

201. **(Previously presented)** The pharmaceutical composition of claim 200, further comprising an additional therapeutic agent selected from the group consisting of budenoside, corticosteroids, cyclosporin, sulfasalazine, aminosalicylates, 6-mercaptopurine, azathioprine, metronidazole, mesalamine, olsalazine, balsalazide, antioxidants, antibodies to IL-1 receptor, anti-IL-1β monoclonal antibodies, anti-IL-6

monoclonal antibodies, pyridinyl-imidazole compounds, anti-TNF antibodies, or fragments thereof, and anti-LT antibodies.

72 ~~202.~~ **(Previously presented)** The pharmaceutical composition of claim ~~200~~ 70, further comprising an additional therapeutic agent selected from the group consisting of anti- IL-1 antibodies, anti-IL-2 antibodies, anti- IL-6 antibodies, anti-IL-7 antibodies, anti-IL-8 antibodies, anti- IL-15 antibodies, anti- IL-16 antibodies, anti-IL-18 antibodies, anti- EMAP-II antibodies, anti-GM-CSF antibodies, anti-FGF antibodies, anti- PDGF antibodies, anti-CD2 antibodies, anti-CD3 antibodies, anti-CD4 antibodies, anti-CD8 antibodies, anti-CD25 antibodies, anti-CD28 antibodies, anti-CD30 antibodies, anti-CD40 antibodies, anti-CD45 antibodies, anti-CD69 antibodies, anti-CD80 (B7.1) antibodies, anti-CD86 (B7.2) antibodies, and anti-CD90 antibodies.

73 ~~203.~~ **(Previously presented)** The pharmaceutical composition of claim ~~200~~ 70, further comprising an additional therapeutic agent selected from the group consisting of methotrexate, FK506, rapamycin, mycophenolate mofetil, leflunomide, non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen, prednisolone, 6-mercaptopurines, soluble p55 TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R, sIL-13, antiinflammatory cytokines, IL-4, IL-10, IL-11, IL-13, TGFβ, Vx740, anti-P7s, p-selectin glycoprotein ligand (PSGL), p75TNFRIgG (Enbrel™), p55TNFRIgG (Lenercept™), pyridinyl-imidazole compounds, anti-gp39 antibodies, anti-CD40L antibodies, methotrexate, cytokine suppressive anti-inflammatory drugs (CSAIDs), leflunomide, MP, mesalazine, chloroquinine/hydroxychloroquine, pencillamine, aurothiomalate, cochicine, salbutamol, terbutaline, salmeteral, theophylline, aminophylline, cromoglycate, nedocromil, ketotifen, ipratropium, and oxitropium.

74 ~~204.~~ **(Previously presented)** The pharmaceutical composition of claim ~~200~~ 70, further comprising an additional therapeutic agent selected from the group consisting of anti-IRAK antibodies, anti-NIK antibodies, anti-IKK antibodies, anti-p38 antibodies, D2E7, cA2 (Remicade™), CDP 571, 5-aminosalicylic acid, TNFR-Ig constructs, dexamethasone, aminosalicylic acid, IL-1ra, methylprednisolone, cyclophosphamide, methotrexate, 4-aminopyridine, tizanidine, interferon-β1a (Avonex™), interferon-β1b

(Betaseron™), Copolymer 1 (Cop-1; Copaxone™), hyperbaric oxygen, clabribine, anti-EMAP-II antibodies, IFNβ1a, IFNβ1b, and IL-1.

205. **(Previously presented)** The isolated human antibody of claim 9, or an antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a K_d of 1.34×10^{-10} M or less.

206. **(Previously presented)** The isolated human antibody of claim 9, or an antigen-binding portion thereof, that binds to human IL-12 and dissociates from human IL-12 with a K_d of 9.74×10^{-11} M or less.

207. **(New)** The neutralizing isolated human antibody of claim 153, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k_{off} rate constant of 1×10^{-3} s^{-1} or less.